The pressure to deliver lifesaving therapies in record time is transforming pharmaceutical operations. Modern software solutions and targeted automation now streamline processes to eliminate errors, reduce complexity, and move promising treatments from the lab bench to commercial manufacturing at unprecedented speed.

In just the last decade, the biopharmaceutical landscape has changed dramatically. Ever since scientists and organisations developed and released the COVID-19 vaccine in record time, quick delivery of new treatments and world-changing life sciences innovations are no longer anomalous, but an expectation.

This shift has put a great deal of pressure on life sciences companies as traditional treatment development methods are not appropriate for this new paradigm. As patients around the world increasingly expect rapid delivery of life-improving and lifesaving treatments, organisations are seeking new operating strategies and technologies to speed drug development. Compressing the time from when companies have a new treatment in development to when they can start producing for clinical trials and, ultimately, for full-scale commercial manufacturing, is paramount.

Fortunately, digital technologies have evolved to meet the changing needs of organisations around the globe. Targeted application of modern software solutions can eliminate wasted time, errors, and complexity that contribute to long development lifecycles. Understanding where delays most commonly originate in the drug development process, and then applying fit-for-purpose solutions designed to build a seamless digital environment from end-to-end, can dramatically shorten the time from discovery to delivery.

Early Phase Digital Transformation Is a Good Start

While modernising commercial drug production with automation software and technologies is commonplace, life sciences companies have also been addressing the need for digital technology in their development pipeline process. Many companies are implementing extensive digital transformation initiatives to move away from traditional paper-based workflows and adopt modern, digital standards, and those initiatives have been highly successful.

In early phases, most organisations moved away from paper records and into digital solutions, like electronic lab notebooks (ELN), to capture and store their data and process/material/equipment specification decisions. This approach significantly reduced the organisational challenges of capturing the complexity of data and managing collaboration within a work team. Teams using ELN are much less likely to lose data or generate errors in transcription of notes, and they frequently improve their long-term record keeping capabilities.

However, digital transformation that ends with an ELN conversion still creates digital silos. ELN software provides a very efficient way to capture unstructured data and retain it for long-term use, but it is often much less capable in making that data easily available further into the development process. But when that type of environment is put in place, teams can take the next steps to begin extracting data from ELN and other software tools and then put it into a broader digital framework so they can use the information more consistently across the development pipeline and enterprise (Figure 1).